

Admetry® User Manual

Pharmacokinetic and Drug Metabolism Data Analysis for Everyone



Nextcea, Inc. • 600 W. Cummings Park • Suite 6375 • Woburn, MA 01801 tel: 800-225-1645 • Admetry@nextcea.com • www.nextcea.com



Admetry® User Manual Registered ® 2010 by Nextcea, Inc. All Rights Reserved Worldwide

Table of Contents



Table of Contents 3

About Admetry® 5

Getting Started 6

- 2.1 Installing Admetry[®] 6
- 2.2 Select Installation Folder 8
- 2.3 Completing Installation 9
- 2.4 Direct Activation (for computers with internet connection) 10
- 2.5 Web Activation (for computers without internet connection) 12

Pharmacokinetic and Toxicokinetic Analysis 15

- 3.1 About PK/TK Analysis 15
- 3.2 Enter dosing regimen 16
- 3.3 Enter route of administration and dosing level 17
- 3.4 Calculate steady state (optional)17
- 3.5 Protein binding (optional) 18
- 3.6 Bioavailability (optional) 18
- 3.7 Bio-analytical data requirements 19
- 3.8 Enter bio-analytical data 19
- 3.9 Submit analysis 21
- 3.10 Editing data after viewing results 21
- 3.11 PK/TK Parameter Tables and Graphics 21
- 3.12 Single-dose results 22
- 3.13 Multiple/Repeat-dose results 23
- 3.14 Determining Bioavailability 24

Clinical Pharmacological Database 25

- 4.1 About Clinical Pharmacological Database 25
- 4.2 Using Clinical Pharmacological Database 26

Human Equivalent Dose Calculation 27

- 5.1 About Human Equivalent Dose Calculation 27
- 5.2 Using HED Calculation 28

Symbol Definitions 29

6.1 About Symbol Definitions 29

Table of Contents

Allometry 30

7.1 About Allometry 7.2 Using Allometry

30 30

In Vitro to In Vivo Drug Metabolism Prediction 31

8.1 About In Vitro to In Vivo Drug Metabolism Prediction 31 8.2 Using Allometry In Vitro to In Vivo Drug Metabolism Prediction 32

Metabolite ID 33

9.1 About Metabolite ID 33

9.2 Using Metabolite ID 34

Drug-Drug Interactions 35

10.1 About Drug-Drug Interactions 35

10.2 Using Drug-Drug Interactions 36

Drug Metabolite Scan 39

11.1 About Drug Metabolite Scan 39

DDI Non-competitive/Competitive 40

12.1 About DDI Non-competitive/Competitive 40

12.2 Using DDI Non-competitive/Competitive 41

IC₅₀ Determination 46

13.1 About IC₅₀ Determination 46 13.2 Using IC₅₀ Determination 47

Technical Support 48

About Admetry®





Admetry[®] is a user friendly software for pharmacokinetic/toxicokinetic and drug metabolism data analysis. It is ideal for those who are new to pharmacokinetics and drug metabolism but also DMPK experts who prefer to perform PK calculations and drug metabolism analysis in an intuitive interface.

PK/TK Analysis	Calculates standard PK parameters (C _{max'} AUC, half-life,) and compares user drug candidate against 500 marketed drugs in humans.	Drug-Drug Interaction	Quickly references FDA preferred and accepted substrates, inhibitors, and inducers of CYP450 isoforms with chemical structures provided.
Metabolite ID	Calculates potential metabolite ions resulting from phase I and phase II metabolic reactions for LC/ MS analysis. Includes example reaction structures.	In Vivo Clearance Prediction	Projects in vivo hepatic clearance based on in vitro S9, microsome, and hepatocyte data.
Allometry	Projects and compares half-life, clearance, or volume of distribution values across multiple species.	Drug Metabolite Scan	Automatically identifies potential Phase I and Phase II metabolites. Additional software license is required.
Human Pharmacology Database	Queries a human pharmacokinetics database of 500 marketed drugs for half-life, volume of distribution, clearance, and chemical structures.	IC50 Determination	Calculates IC ₅₀ values and graphs inhibition data
Human Equivalent Dose	Calculates the human equivalent dose from any animal model based on body surface area and body weight.	DDI Non-competitive/ Competitive	Calculates drug-drug competitive and non- competitive interactions using 4 different models.

Getting Started



2.1 Installing Admetry®

Installing Admetry[®] is easy. Admetry[®] Setup Wizard will start automatically upon inserting CD.

If Setup Wizard does not start automatically:

- Insert Admetry[®] CD
- Open "My Computer"
- Double click Admetry® Setup icon







• Click "Next"



Getting Started



2.2 Select Installation Folder

- Specify the directory where Admetry® will be installed
- Choose "Everyone" or "Just me" installation options depending on who will be using Admetry[®]
- Click "Next"

🛃 Admetry	
Select Installation Folder	
The installer will install Admetry to the following folder.	
To install in this folder, click "Next". To install to a different folder, enter it be	low or click "Browse".
<u>F</u> older: C:\Program Files\Nextcea\Admetry\	Browse Disk Cost
Install Admetry for yourself, or for anyone who uses this computer:	
 Everyone 	
🔿 Just me	N.
Cancel < Back	Next >

extcea

Getting Started

2.3 Completing Installation

• Admetry will install (please be patient as it normally takes a few minutes) Note: Microsoft .NET Framework version 3.5 is required. If you do not have Microsoft .NET Framework 3.5, Admetry will install it to your computer automatically.

• Click "Close" to complete the installation

😸 Admetry			
Installation Complete			
Admetry has been successfully installed.			
Click "Close" to exit.			
Please use Windows Update to check fo	r any critical update	s to the .NET Fram	ework.
	Cancel	< Back	Close





Activating Admetry[®] V

When Admetry[®] first opens after installation you will be prompted to activate the software. You can activate Admetry[®] via **Direct Activation** or **Web Activation**.

After purchasing an Admetry[®] license, Nextcea will email you an activation CD key.

2.4 **Direct Activation** (for computers with internet connection)



Please allow a few minutes to connect to Nextcea's server for activation.

Getting Started



- If activation is successful, "Activation Status" will read "Activated"
- If activation is not successful, the CD key may already be registered.

Please note that each CD key is only allowed to be installed onto one computer per license.

Email Admetry@nextcea.com should you experience any problems during activation.

Getting Started



2.5 Web Activation (for computers with limited internet access)

Web activation is intended for computers with internet activation problems due to firewall, limited internet access, or no internet access.

Note: This method requires a **flash drive** to transfer small files



Type or Paste in the CD Key found in the Admetry® activation email from Nextcea.



An **authentication code** will be generated in the text box.

Click "Copy Authentication Code" to copy the code to your clipboard.

- **3** Paste the **authentication code** into Notepad and save the file on a flash drive.
- 4 On a computer with internet access, log onto: https://nextcea.com/web/PkTk/PublicContent/AuthorizeAdmetry.aspx
- 5 Copy and paste the authentication code into the textbox labeled "Please enter your authentication code". Click "Submit".
- 6

Copy the **Authorization Code** from the textbox below and paste it back into Notepad and save it on the flash drive. Return the flash drive to the original computer with Admetry[®] installed and paste the **Authorization Code** into the Authorization Code textbox.



Click "Activiate Admetry".





Please enter valid CD key and click Verify button to create authentication code:
CD Key: 6QWE3-QDNT5-GFPA4-896SE-21GFV (SAMPLE CD KEY)
Direct Activation Web Activation
Authentication Code:
04wSDFfsfw3w3223490vmdlvj3490fjw eDK3r-f9asdfjdsfqqeb3#(3fr09jc;df4g tbvdcvxcvbCEef=
Obtain you authorization code by enter your authentication code to web page:
https://nextceainc.com/PkTk/PublicContent/AuthorizeAdmetry.aspx
Authorization Code: 6 Paste Authorization Code
Activation Status:
Not Activated! Cancel

Admetry[®] should now be activated. If activation is not successful, the CD key may already be registered. Email Admetry@nextcea.com should you experience any problems during activation.





(Step 5. Obtaining the Authorization Code through Nextcea's website)



If activation is successful, Activation Status will read "Activated"

If activation is not successful, the CD key may already be registered. Email Admetry@nextcea.com should you experience any problems during this step.



3.1 About PK/TK Analysis



PK/TK Analysis includes modules for single, repeat, and multiple-dose analysis and calculations are based on non-compartmental models. Intravenous (IV) or extra-vascular (ie. oral, subcutaneous, topical, inhalation, rectal or percutaneous) dose analysis are available. Concentration-time data can be entered manually or imported from Excel using the data paste function. The results are presented graphically and in list form.

3.2 Enter dosing regimen

- Enter Study Protocol/Title (optional)
- Select animal species and gender (optional)

Note: If animal species **is not** selected, the resulting PK parameters will be displayed in "per kg" units. If animal species **is** selected, the resulting PK parameters will include "per m²" in addition to "per kg".

CNextcea

Jnits with	hout spec	cies selected	Units v	with species selected
Vz	52.8	mL/kg	Vz	52.8 mL/kg
V _{ss}	36.6	mL/kg		158 mL/m ²
CL	5.91	mL/hour/kg	V _{ss}	36.6 mL/kg
				110 mL/m ²
			CL	5.91 mL/hour/kg
				17.7 mL/hour/m ²

- Select standard body weight or enter a specified body weight (optional)
- Select single, repeat, or multiple-dose regimen
- Select dose by weight or surface area

PharmacoKinetic And ToxicoKinetic Analysis

Tutorial PK/TK Data

Study Protocol/Title:					
Species:	Unspecified	~	Strain/Type:	N/A	
Body Weight:	Unspecified	×			
Dose By:	Weight (kg)	~	Gender:	Combined Gender 💌	-0-
Single or Multiple Adr	ninistration:	Single admini	stration of one dose	e level 🛛 💌	



3.3 Enter route of administration and dosing level

- Select IV and/or Extravascular Dose checkbox for route of administration
- Specify the dose level

Select checkbox for route of administration IV Dose	Select checkbox for route of administration Extravascular Dose (Oral, Tropical, Inhalation, Percutaneous, Rectal, Transdermal and Subcutaneous)
Option One) Calculate steady state after repeat dose	Calculate steady state after repeat dose
Dose Interval: Minute 💌	Dose Interval: Minute 💌
Dose Time: 0 Minute 💌	Dose Time: 0 Minute 🗸
Option Two)	(Option Two)
	Bioavailability: 1
Protein Binding: 0 %	Protein Binding: 0 %
Dose: 2.5 mg 🖌 /kg	Dose: mg 🖌 /kg

3.4 Calculate steady state (optional)

- Select checkbox for steady state calculation after repeat dose
- Enter dose interval and time

 (Option One) Calculate steady state 	after repeat dose
Dose Interval:	24 Hour 💌
Dose Time:	8 Hour 💌

3.5 Protein binding (optional)

Inputting protein binding data from dialysis studies is strongly recommended to accurately determine in vivo and in vitro PK parameters. If protein binding data is not included, Admetry[®] defaults protein binding as 0%.



When preparing samples for PK analysis the drug extraction procedure artificially dissociates the drug from plasma/serum proteins (ie. protein binding = 0%) by organic solvents (acetonitrile, methanol).

• Specify protein binding (%)

— (Option Two)—	
Protein Binding:	25 %

CNextcea

3.6 Bioavailability (optional)

Inputting bioavailability data is also strongly recommended to accurately determine in vivo and in vitro PK parameters. If bioavailability data is not included, Admetry[®] defaults bioavailability as 100%.

- Specify bioavailability if known (oral administration only)
- Determine bioavailability by following the steps in Section 3.14



3.7 Bio-analytical data requirements

The bio-analytical data requirements for single, repeat and multiple/repeat-dose analysis are listed below.

- Single administration of one dose level (Time, Concentration)
- Single-dose with one different levels (Dose Level, Time, Concentration)
- Multiple/Repeat-dose with different dose levels (Dose Level, Schedule, Time, Concentration)



Admetry[®] recognizes the term "BLQ" as a concentration below the limit of quantitation. It does not convert "BLQ" concentration entries to zero. Instead, Admetry[®] excludes data points with "BLQ" concentrations in all PK/TK parameter calculations.

When inputting bio-analytical data for single oral dose, the first data point should be time= 0, concentration= 0.

3.8 Enter bio-analytical data

Bio-analytical data may be entered for single or multiple patients/animals. Enter data for multiple animals sequentially. As an example, enter all concentrationtime data for patient one followed by all concentration-time data for animals two and three. Concentration entries of matching time points are averaged prior to PK/TK analysis.

• Enter bio-analytical data manually or with the Paste Bio-analytical Data function



How to input bio-analytical data from Excel:

• Copy data from Excel spreadsheet

	A	В	С	D
1	Single Ad	Iministration of	One Dose	e Level
2				
3	IV			
4	Dose	1	mg/kg	
5				
6	Time (hr)	Conc (ng/mL)		
7				
8	0.017	48445.0		
9	0.083	40970.0		
10	0.250	25045.0		
11	0.500	23518.0		
12	0.750	17791.0		
13	1.000	21477.0		
14	2.000	12430.0		
15	3.000	13184.0		
16	4.000	10408.0		
17	6.000	8052.0		
18	24.000	321.0		
19	48.000	233.0		
20				
21				

In Admetry[®] window click
 "Paste Bioanalytical Data"



Identify the columns and click "OK" (Note: As a default, Column 1 is set to "Time" and Column 2 is set to "Conc")

Paste Bio	analytical Data			×
Please sele data.	ct your paste data for	mat first, then click "C)K" to process pasted	ł
Column 1	Column 2	Column 3	Column 4	
Time	Conc	▼	~	~
0.017	48445.0			~
0.083	40970.0			
0.250	25045.0			
0.500	23518.0			
0.750	17791.0			=
1.000	21477.0			
2.000	12430.0			
3.000	13184.0			
4.000	10408.0		×	
6.000	8052.0			~
			Cancel	K

extcea



3.9 Submit analysis

- View results

To reset ALL data input, click



3.10 Editing data after viewing results

- Click "Back To Data Entry" in the PK/TK Analyzer results page to return to data entry
- Click "Save To User Database" and enter in a brief description of the results
- Click "Export To Excel" to save data in Microsoft Excel format



3.11 PK/TK Parameter Tables and Graphics

PK/TK parameters are viewed in downloadable tables and graphics. Users can select the number of significant digits to report.

3.12 Single-dose results

PK/TK Parameters

IV Dose Parameters				
Parameter Name	Value	Unit		
Dose Level	5.00	mg/kg		
Protein Binding	0.00%			
C _o	5.06e+4	ng/mL		
C _{max}	4.84e+4	ng/mL		
t _{max}	0.0170	hour		
t _{1/2} (Terminal Phase)	6.54	hour		
t _{1/2} (Distribution Phase)	0.273	hour		
AUC _(0-t)	1.67e+5	hour*ng/mL		
AUC _∞	1.70e+5	hour*ng/mL		
AUMC _(0-t)	9.27e+5	hour*hour*ng/mL		
AUMC _∞	1.05e+6	hour*hour*ng/mL		
MRT	6.21	hour		
Vz	278	mL/kg		
	835	mL/m ²		
V _{ss}	183	mL/kg		
	549	mL/m ²		
CL	29.5	mL/hour/kg		
	88.4	mL/hour/m ²		
C _{max} /Dose	9.69e+3	(ng/mL)/(mg/kg)		
	2.91e+4	(ng/mL)/(mg/m ²)		

Drug concentration vs. time graph

CNextcea



PK/TK Allometric Visualizer

The calculated PK values from all different animal species are allometrically converted to human PK values and then compared against 500 marketed drugs in the human clinical PK database.

PK/TK Allometric Visualizer







Volume of Distribution & Clearance Meter

Displays 3 levels (low, medium, high) of each species. Volume of distribution meter is determined by intracellular + extracellular fluid (total body fluid) in individual animal species. Clearance meter is determined by the total blood flow of liver and kidneys in individual animal species.

Volume of Distribution

Low = <30% total body fluid Medium = >30% and <70% of total body fluid High = >70% of total body fluid

> An animal icon will be displayed when an animal species is selected during data entry.



Low = <30% total blood flow Medium = >30% and <70% of total blood flow High = >70% of total blood flow



3.13 Multiple/Repeat-dose results







3.14 Determining Bioavailability

- Select checkboxes for both IV and extravascular routes of administration (ie. oral, topical, subcutaneous etc...)
- Enter IV and extravascular routes dose levels and bio-analytical data into Admetry®
- Click calculate button



• Bioavailability is reported in the PK/TK parameters table

PharmacoKinetic / ToxicoKinetic Parameters

IV Dose Parameters			Oral Dose Parameters			
Parameter Name	Value	Unit	Paramete	er Name	Value	Unit
Dose Level	1.00	mg/kg	Dose Level		5.00	mg/kg
Protein Binding	0.00%		Protein Bindi	ng	0.00%	
			Bioavailabilit	y (F)	1.65%	
C _o	0.00	ng/mL	C ₀		0.00	ng/mL
C _{max}	4.84e+4	ng/mL	C _{max}		902	ng/mL
t _{max}	0.0170	hour	t _{max}		4.00	hour

Clinical Pharmacological Database



4.1 About Clinical Pharmacological Database



The clinical pharmacological database contains 500 marketed drug compounds in humans. Users can instantly find valuable human PK parameters based on a variety of search options. By pointing to a drug, the structure, chemical formula, therapeutic class, human PK (ie. bioavailability, clearance,...) will be displayed.

Clinical Pharmacology Database

Half Life (hr): Volume of Distribution (L/kg): Clearance (mL/min*kg): Or search by Drug Name	1 to	2 Sear	ch
Drug	Clearance (mL/min kg)	Volume Distribution (L/kg)	Half- Life (hr)
Drug Benzocaine	Clearance (mL/min kg) 21.2	Volume Distribution (L/kg) 1.04	Half- Life (hr) 1.75
Drug Benzocaine Cefotaxime (Claforan)	Clearance (mL/min kg) 21.2 7.5	Volume Distribution (L/kg) 1.04 1.2	Half- Life (hr) 1.75 1.2
Drug Benzocaine Cefotaxime (Claforan) Cimetidine (Tagamet)	Clearance (mL/min kg) 21.2 7.5 8.3	Volume Distribution (L/kg) 1.04 1.2 1	Half- Life (hr) 1.75 1.2 2
Drug Benzocaine Cefotaxime (Claforan) Cimetidine (Tagamet) Cromolyn (Opticrom)	Clearance (mL/min kg) 21.2 7.5 8.3 15.6	Volume Distribution (L/kg) 1.04 1.2 1 1.8	Half- Life (hr) 1.75 1.2 2 1.3

Clinical Pharmacological Database



4.2 Using Clinical Pharmacological Database

- Input a range of search values for either Half Life, Volume of Distribution, and/ or Clearance
- Type in drug name (optional)
- Click "Search"
- Scroll over compounds to view the PK parameters and drug information

Clinical Pharmacology Database

Half Life (hr): Volume of Dist Clearance (mL, Or search by	ributic /min*k Drug Na	on (L/kg):	0.5 to	1 Search 2 Search	
Drug	Clea	rance (mL/min kg)	Volume Distributi	on (L/kg) Half-Life (hr)
Cocaine	32		2	0.8	
Flumazenil	17		1	0.9	
Glyco ^h)rrolate (Robinul)	30		1.4	0.5	
Hydralazine	56				
Penicillamine (Cuprimine)	9.3		Flumazenii		
		Bioavailability (oral, %	6): 20		
		Clearance (mL/min kg): 17		
		Volume Distribution (L	./kg): 1		
		Half-Life (hr):	0.9		
		Therapeutic Class:	Sedative effects	of benzodiazepines	
		Chemical Formula:	С ₁₅ Н ₁₄ FN ₃ О ₃		
		Molecular Weight:	303.2884		
		F			



This tool converts animal doses to human equivalent doses (HED) based on body surface area. The HED calculations are based on recommendations by the Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (FDA/CDER, 2005).

Human Equivalent Dose Calculation

5.2 Using Human Equivalent Dose Calculation

- Specify the species from the "Species" dropdown menu
- Input the Animal Body Weight manually by selecting "Standard body weight" or "Specified body weight" and enter the weight manually
- Enter the Animal Dose Level in mg/kg
- Select Adult or Child and specify the Human Body Weight
- Click to
 - to project human equivalent dose levels

Human Equivalent Dose Calculation

Admetry[®] calculates animal doses to human equivalent doses (HED) based on body surface area. The HED calculations are based on recommendations by the Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (FDA/CDER, 2005).

Species:	Mouse
Animal Body Weight:	Standard body weight 💌
Animal Dose Level:	mg/kg
Human Body Weight:	Adult V Standard body weight V
Human Equivalent Dose Level:	mg/kg
	mg/m ²

Symbol Definitions



6.1 About Symbol Definitions



Common pharmacokinetic and toxicokinetic symbols are explained.

Symbol Definition

AUC _{0-t} :	Area under the plasma rug concentration-time curve from time 0 to time t
AUC∞:	Area under the plasma rug concentration-time curve from time 0 to time infinity
AUMC ₀₋	Total area under the first moment time curve from time 0 to time t
ť	
AUMC∞:	Total area under the first moment time curve from time 0 to time infinity
C ₀ :	Initial plasma concentration
C _{ss, avg} :	Average drug concentration in plasma at steady state
C _{max} :	Highest drug concentration observed in plasma following administration of IV or oral dose
C _{ss, max} :	Maximum drug concentration in plasma at steady state. $C_{ss, min} = F^* D_L / V (1 - e^{-\lambda \tau})$
C _{ss, min} :	Minimum drug concentration in plasma at steady state. $C_{ss, min} = F^* D_L^* e^{-\lambda \tau} / V (1 - e^{-\lambda \tau})$
CL:	Total systemic clearance of drug from plasma
CL _{ss} :	Total systemic clearance of drug from plasma at steady state. CL_{ss} = Dose / AUC _{0-T}



7.1 About Allometry



Allometry is used to predict PK parameters across different species.

7.2 Using Allometry

- Specify the species from the "Species" dropdown menu
- Enter any 2 of either half life, clearance, or volume of distribution
- Click "Calculate" to generate PK parameters for all other animal species

		Spe	cies:	Adult		*						
	E	Enter a	ny two	of t _{1/2} ,	CL, and	v						
	Ha	lf-life (t _{1/2}):				Hour	*				
	Clea	arance	(CL):			m	L/min	*				
Volum		Rodent	Species			Non-Rodent Species			Primates			
		t _{1/2}	CL	v		t _{1/2}	CL	V		t _{1/2}	CL	v
	Mouse:	0.053	0.000	0.000	Rabbit:	0.187	0.002	0.043	Monkey:	0.216	0.003	0.069
	Hamster:	0.078	0.000	0.002	Dog:	0.303	0.006	0.214	Marmoset:	0.118	0.000	0.009
	Rat:	0.093	0.000	0.004	Micro-	0.368	0.010	0.411	Squirrel	0 138	0.001	0.015
	Ferret:	0.113	0.000	0.008	Pig:	0.500	0.010	0.411	Monkey:	0.130	0.001	0.015
	Guinea	0 123	0.000	0.010	Mini-	0.446	0.015	0.789	Baboon:	0.319	0.007	0.254
	Pig: 0.123 0.000 0.010			Fig.				<u>ال</u>	Hun	nan		
									Child:	0.368	0.010	0.411
									Adult:	0.500	0.020	1.155





8.1 About In Vitro to In Vivo Drug Metabolism Prediction



This tool is used to predict in vivo clearance values for a species based on well-stirred and parallel-tube models.

In Vitro to In Vivo Drug Metabolism Prediction



8.2 Using In Vitro to In Vivo Drug Metabolism Prediction

- Specify the species from the Species dropdown menu
- Enter in vitro half life, $t_{1/2}$ (min) and incubation volume (mL)
- Input the Animal Body Weight manually by selecting "standard body weight" or "specified body weight" and enter the weight manually
- Specify f_u (unbound fraction in blood)
- Enter the amount (mg) of microsomes, S9, or number of hepatic cells used
- Click "Calculate" to predict in vivo clearance values

In Vitro to In-vivo Drug Metabolism Prediction

Species:	Mouse 💌	
In Vitro T _{1/2} :		min
Incubation Volume:		mL
Body Weight:	Standard Body Weight	*
	0.02	kg
f _u (unbound fraction in blood):	15	%
Microsome:		mg
O S9:		mg
○ Hepatocyte Cells:		million(s)
CL _{int} (In-vitro intrinsic clearance):		mL/min/kg
Well-stirred model (In-vivo hepatic clearance, CL_h):		mL/min/kg
Parallel-tube model (In-vivo hepatic clearance, CL _h):		mL/min/kg

Metabolite ID



9.1 About Metabolite ID



Metabolite ID is used to quickly generate all possible metabolites to identify when looking for Phase I and Phase II metabolites.

Metabolite ID

9.2 Using Metabolite ID

- Enter the Exact Mass of the parent compound
- Select either positive or negative ionization method: (M+H)+ or (M-H)-
- Check any number of Phase I and/or Phase II metabolisms based on the structure of the drug candidate if possible
- Click
- to ge

to generate a list of possible metabolite ion values

Note: Scroll over the metabolite ion values to see the corresponding metabolic reactions.

Metabolite ID

Exact Mass: 523 Ionizati	on Method: (M	I+H)+ 🔽 🧾	Calculate	
Drug Metabolism	Calculated Metabolite Results			
Phase I Metabolites	0.00	Tura	Two	Three
✓ Hydrogenation	Departien	Two Reactions	Combined	Combined
Hydroxylation, Oxidation, Epoxidation (Aromatic &	Reaction	Reactions	Reactions	Reactions

Alighteric			Reactions	Reactions
Aliphauci	451 0066	270.0654	lb 400.076	411.0017
✓ S-Oxidation	451.9800	379.9054	409.970	411.9917
P-Oxidation (S replacement)	481.9972	439.9866	454.0023	425.9709
 Hydrolysis (Ester, O=C-O-CH3 -> OH) 				
Hydrolysis (Ester, O=C-O-CH2-CH3 -> O=C-OH)	526.0235	528.0392	467.9815	425.9709
Hydrolysis (Amide, O=C-NH-CH3 -> OH)	540.0027	555.9976	467.9815	469.9972
 Hydrolysis (Amide, O=C-NH-CH2-CH3 -> NH2) 	E40.0007	EEE 0076	484.0120	460.0070

- N_{extcea}

Drug-Drug Interactions

10.1 About Drug-Drug Interactions



Drug-drug interaction is a quick reference for in vitro and in vivo drug-drug interaction study designs.

Drug-Drug Interactions

10.2 Using Drug-Drug Interactions

DDI Table

- Shows FDA preferred substrates, inhibitors, and inducers of the major CYP450 isoforms
- Scroll over any compound to see the metabolic reaction, chemical structure,

formula, and exact mass

DDI Table In Vitro	Table	e 🛛 In Vivo Table						
	Drug-Drug Interaction							
CY	ΥΡ	Substrate	Inhibitor	Inducer				
142	2	Phenacetin	Furafylline	Omeprazole				
246	6	Coumarin	Tranylcypromine	Dexamethasone				
384	4/5	Midazolam Testoerone	Ketoconazole	Rifampin				
286	6	Bupropion	Ticlopidine	Phenobarbital				
208	В	Amodiaquine	Quercetin	Rifampin				
209	9	Tolbutamide	Sulfaphenazole	Rifampin				
201	19	S-mephenytoin	Omeprazole	Rifampin				
206	6	Dextromethorphan	Quinidine	Dexamethasone				
2E1	1	Chlorzoxazone	Diethyldithiocarbamate	Isoniazid				

Drug Drug Interaction

Drug-Drug Interactions

N_{extcea}

In Vitro Table Table

• Shows FDA preferred and accepted substrates, inhibitors, and inducers of the

major CYP450 isoforms for in vitro studies

Note: Based on "Guidance to the Industry" documents, using the "preferred" list of substrates, inhibitors, and inducers is strongly encouraged, however the FDA will accept data generated using compounds in the "accepted" list.

• Scroll over any compound to see the metabolic reaction, chemical structure,

formula, and exact mass

Dru	g Drug In	terad	ction						
DDI	Table In Vitro Ta	ble In	Vivo Table						
	In Vitro Table								
CY	P	Subs	trate				Inh	nibitor	
	Preferred	Km (µM)	Accepted	Km (µM)	Preferred	Ki(µM)		Accepted	
			7-ethoxyresorufin- O-deeth ption	0.18- 0.21					
142	Phenacetin-O-	-0- 1.7-	Theophylline-N- demethylation	Ethoxyresorufin				aphthoflavone	
	deethylation	*5.14	Caffeine-3-N- demethylation						
246	Coumarin-7- hydroxylation	0.30- 2.3			Chemical Formula: C14H1 Exact Mass: 241.07	1NO3		carpine	
	Nicotine C- oxidation	13-162			Methoxsalen	0.01- 0.2	Tryp	otamine	

Drug-Drug Interactions

In Vivo Table Table

• Shows FDA preferred and accepted substrates, inhibitors, and inducers of the

major CYP450 isoforms for in vivo studies

Note: Based on "Guidance to the Industry" documents, using the "preferred" list of substrates, inhibitors, and inducers is strongly encouraged, however the FDA will accept data generated using compounds in the "accepted" list.

• Scroll over any compound to see metabolism reaction, chemical structure,

formula, and exact mass

Drug Drug Interaction

DDI Table In Vitro Table In Vivo Table								
In Vivo Table								
CYP	Qubatrata		Inhibitor		Tura ale una sua			
	Substrate	Strong	Moderate	Weak	Inducer			
1A2	Theophylline Caffeine *1.4 +/- 0.5	Fluvoxamine	Acyclovir Famotidine Norfloxacin Verapamil Cimetidine *8.3 +/- 2	Ciprofloxacin Mexiletine Propafenone Zileuton				
2B6	Efavirenz				Rifampin			
2C8	Repaglinide Rosiglitazone	Gemfibrozil	Trimethoprim		Rifampin			

extcea

Drug Metabolite Scan

11.1 About Drug Metabolite Scan



Drug Metabolite Scan is a utility to help automate the drug metabolite identification process.

Note: Additional software license is required.

A converted .wiff file from Analyst (QSTAR LC/MS/MS) to a specify data format is required to use this function.

DDI Non-competitive/Competitive

12.1 About DDI Non-competitive/Competitive



Non-Competitive/Competitive Drug-Drug Interaction calculates drug-drug interactions using Michaelis-Menten-Henri, Lineweaver-Burk, Hanes-Woolf, and Eadie-Hofstee models.

extcea

DDI Non-competitive/Competitive

12.2 Using DDI Non-competitive/Competitive

Enter background study design information:

- Study Title
- Compound Name
- Species
- Strain
- CYP450 Enzymes, Incubation Time, and Inhibitor Concentration

DDI Non-competitive/Competitive

Study Title: Compound (Drug Candidate) Names:]	
Incubation Time		min 💌	0
Inhibitor Concentration:		ng/mL 💌	
Species:	Mouse 💙 St	rain/Type: CD-1	*
CYP P450 Enzymes:	Microsomes 👻		
Paste Data Clear Data			
Substrate Conc Pro ng/mL ❤ With	oduct Conc 👻 🛛 P nout Inhibitor 🛛 W	roduct Conc /ith Inhibitor	
1			

DDI Non-competitive/Competitive



• Copy drug-drug interaction data from Excel

	А	В	С		D	E			
1		V (Velocity), um	ol/min						
2	[S], uM	No inhibition							
3	3	10.4		4.1					
4	5	14.5		6.4					
5	10	22.5		11.3					
6	30	33.8		22.6					
7	90	40.5		33.8					
8									
9			-						
10	Inhibitor Conc = 2mM = 2000 uM								
11				- h	n Exc				
12									
13									

• In Admetry[®], click "Paste Data"

DDI Non-competitive/Competitive

Study Title: Compound (Drug Candidate) Names:	NEX008	
Incubation Time Inhibitor Concentration:	30 min 🗸	5
Species: CYP P450 Enzymes:	Mouse Strain/Type: CD-1	
Paste Data Clear Data		
Substrate Conc Pro ng/mL V Wit	Product Conc Product Conc ithout Inhibitor With Inhibitor	
1		

extcea

DDI Non-competitive/Competitive

Note:

Make sure data is copied from columns in the following order from left to right:

Substrate concentration \rightarrow Velocity without inhibition \rightarrow Velocity with inhibition

• Click "OK"

F	Paste	User Data				×
	Please	paste (use ctr	l+v) your	data into text b	ox below then	press OK button.
	3	10.4	4.1			~
	5	14.5	6.4			
	10	22.5	11.3			
	30	33.8	22.6			
	90	40.5	33.8			
						~
						Cancel OK

• Click "Calculate" to calculate to graph results.

DDI Non-competitive/Competitive NEX008 Study Title: Compound (Drug Candidate) Names: NEX008 Incubation Time 30 min 💌 2.5 ng/mL 💌 Inhibitor Concentration: Strain/Type: CD-1 Species: Mouse CYP P450 Enzymes: Microsomes 🗸 Clear Data Paste Data Substrate Conc Product Conc 🗸 Product Conc ng/mL 🔽 With Inhibitor Without Inhibito 3 10.4 4.1 1 5 14.5 6.4 2 3 10 22.5 11.3 30 33.8 22.6 4 5 90 40.5 33.8 6

DDI Non-competitive/Competitive

- Select either "Non-Competitive" or "Competitive" inhibition based on the resulting graph
- Note: Non-Competitive Inhibition graphs intersect on the Y-axis (1/V) Competitive Inhibitions graphs intersect on the X-axis (1/[S])



extcea

DDI Non-competitive/Competitive

- The results are graphed using Michaelis-Menten-Henri, Lineweaver-Burk, Hanes-Woolf, and Eadie-Hofstee equations
- $K_{m'}$, $V_{max'}$, and K_{i} are calculated
- Click "Save to User Database" to save
- Click "Back to Data Entry" to go back to background study design information





This function calculates of the effectiveness of a compound in inhibiting biological function. It calculates the half maximal inhibitory concentration (IC_{50}) from submitted substrate concentration information.



extcea

IC₅₀ Determination

13.2 Using IC₅₀ Determination

- Select either "% of P450 Inhibition" or "Substrate and Inhibitor Conc" data input
- Manually enter or paste in data from Excel
- Click calculation button



• View results, IC₅₀ is calculated

IC₅₀

Sele % o	ct user input data forma f P450 Inhibition	at:	\mathbf{k}		Calcu	llate										
Paste Data Clear Data		0					10	IC50=17.50								
	% of P450 Inhibition	Inhibitor Conc			100 -	•		> •	•		۰	-				
1	98	0.000508		*	00											
2	102	0.00152		of f	00							Ĭ	•			
3	94	0.00457		9450	60 -									•		
4	96	0.0137		Į.		<u> </u>								-		
5	96	0.0412		ibitio	40 -											
6	97	0.123		5	20											
7	90	0.37			20 -											
8	80	1.11			0 -		_									
9	70	3.33			0.0	0001 0	0.00	1 (0.01	0).1	1		10	100	
10	59	10)rug	(uM)				
11	35	30														
12																

Technical Support

For questions or comments about Admetry® Desktop please contact Nextcea:



Admetry@nextcea.com



(800) 225-1645 toll free (781) 457-4010



Nextcea, Inc. 600 W. Cummings Park #6375 Woburn, MA 01801 phone: 800-225-1645 fax: 617-812-2684 Admetry@nextcea.com